Zevra Therapeutics Inc. (ZVRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zevra Therapeutics Inc. (ZVRA) has a cash flow conversion efficiency ratio of 0.035x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($4.71 Million) by net assets ($133.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Zevra Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Zevra Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ZVRA total debt and obligations for a breakdown of total debt and financial obligations.
Zevra Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zevra Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suzhou Kelida Bldg &
SHG:603828
|
0.085x |
|
Bridgewater Bancshares Inc
NASDAQ:BWB
|
0.030x |
|
Ennis Inc
NYSE:EBF
|
0.054x |
|
MIDEA REAL HLDG HD 1
F:MR9
|
N/A |
|
Invesco Quality Municipal Income Closed Fund
NYSE:IQI
|
0.018x |
|
Beta Bionics, Inc. Common Stock
NASDAQ:BBNX
|
-0.030x |
|
Anhui Wanyi Science and Technology Co Ltd
SHG:688600
|
0.066x |
|
Qijing Machinery
SHG:603677
|
0.056x |
Annual Cash Flow Conversion Efficiency for Zevra Therapeutics Inc. (2012–2024)
The table below shows the annual cash flow conversion efficiency of Zevra Therapeutics Inc. from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see ZVRA company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $39.67 Million | $-69.67 Million | -1.756x | -223.99% |
| 2023-12-31 | $61.86 Million | $-33.53 Million | -0.542x | -117.56% |
| 2022-12-31 | $75.12 Million | $-18.72 Million | -0.249x | -403.41% |
| 2021-12-31 | $127.12 Million | $10.44 Million | 0.082x | +181.27% |
| 2020-12-31 | $-66.41 Million | $-1.94 Million | 0.029x | -90.84% |
| 2019-12-31 | $-74.46 Million | $-23.74 Million | 0.319x | -60.85% |
| 2018-12-31 | $-66.57 Million | $-54.20 Million | 0.814x | +41.49% |
| 2017-12-31 | $-57.52 Million | $-33.10 Million | 0.575x | -63.86% |
| 2016-12-31 | $-18.70 Million | $-29.77 Million | 1.592x | -20.48% |
| 2015-12-31 | $-10.12 Million | $-20.27 Million | 2.003x | +231.64% |
| 2014-12-31 | $-24.30 Million | $-14.67 Million | 0.604x | +238.65% |
| 2013-12-31 | $-24.27 Million | $-4.33 Million | 0.178x | -97.48% |
| 2012-12-31 | $-627.22K | $-4.43 Million | 7.070x | -- |
About Zevra Therapeutics Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under P… Read more